Drugs / ACTINIUM DOTATATE
ACTINIUM DOTATATE
also known as
RYZ101 · 225Ac-DOTATATE · 225ac-oxodotreotide · ACTINIUM AC 225 DOTATATE · Actinium oxodotreotide ac-225 · Oxodotreotide ac-225
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06411301 | Oct 2024 → Oct 2026 | plasma cell myeloma | Jules Bordet Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT05595460 | Oct 2022 → Jul 2027 expected | small cell lung carcinoma | RayzeBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07150806 | Nov 2025 → Dec 2026 expected | meningioma | Joshua Palmer | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06590857 | Jul 2024 → Oct 2028 expected | hormone receptor-positive breast cancer, metastatic carcinoma in the bone | RayzeBio, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05477576 | Mar 2022 → Dec 2026 expected | carcinoid tumor, pancreatic neuroendocrine tumor | RayzeBio, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-13 | RayzeBio, Inc. | Regulatory RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications rayzebio.com ↗
Additionally, RayzeBio received Investigational New Drug Application (IND) clearance from the U.S. Food and Drug Administration (FDA) to investigate RYZ101 for first-line treatment of patients with SSTR+ extensive-stage small cell lung cancer (ES-SCLC) in combination with standard of care. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-31 | RayzeBio, Inc. | RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors rayzebio.com ↗ |
| 2023-03-20 | RayzeBio, Inc. | RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors rayzebio.com ↗ |
| 2023-01-04 | RayzeBio, Inc. | RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE) rayzebio.com ↗ |
| 2022-09-13 | RayzeBio, Inc. | RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications rayzebio.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACTINIUM DOTATATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772 ↗ |
| Known as | 225Ac-DOTATATE | “I. To estimate the efficacy of 225Ac-DOTATATE (RYZ101) therapy in the treatment of patients with progressive or recurrent grade 1-3 intracranial meningioma as measured by the...” NCT07150806 ↗2“Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.” NCT06590857 ↗ |
| Known as | 225ac-oxodotreotide | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772 ↗ |
| Known as | ACTINIUM AC 225 DOTATATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772 ↗ |
| Known as | Actinium oxodotreotide ac-225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772 ↗ |
| Known as | Oxodotreotide ac-225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068772 ↗ |
| Known as | RYZ101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06590857 ↗ |
| Modality | Other / unclassified | “It is a type of radioconjugate and a type of somatostatin analog.” NCT07150806 ↗ |
| Route | Intravenous | “Two intravenous infusions every 6 weeks (Q6W)” NCT06411301 ↗ |